STOCK TITAN

electroCore to Announce First Quarter 2022 Financial Results on May 5

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

ROCKAWAY, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2022, after the close of the market on Thursday, May 5, 2022. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.

Thursday, May 5, 2022, 4:30 PM EDT
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13728177 
Webcast: electroCore Earnings Webcast

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com

Contact:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital

 


ElectroCore Inc

NASDAQ:ECOR

ECOR Rankings

ECOR Latest News

ECOR Stock Data

Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Health Technology, Medical Specialties, Manufacturing, Electromedical and Electrotherapeutic Apparatus Manufacturing
United States

About ECOR

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.